Otsuka Ryo, Seino Ken-Ichiro
Institute for Genetic Medicine, Hokkaido University, Kita-15, Nishi-7, Sapporo, Hokkaido 060-0815 Japan.
Inflamm Regen. 2020 Aug 6;40:19. doi: 10.1186/s41232-020-00131-w. eCollection 2020.
An emerging, rapidly spreading coronavirus SARS-CoV-2 is causing a devastating pandemic. As we have not developed curative medicine and effective vaccine, the end of this life-threatening infectious disease is still unclear. Severe COVID-19 is often associated with hypercytokinemia, which is typically found in macrophage activation syndrome. SARS-CoV-2 infection causes this strong inflammation within the lung and propagates to respiratory and, ultimately, systemic organ malfunction. Although we have not fully understood the physiological and pathological aspects of COVID-19, current research progress indicates the effectiveness of anti-cytokine therapy. Here, we summarize macrophage activation syndrome and its possible contribution to COVID-19, and cytokine targeted attempts in severe COVID-19 cases.
一种新出现的、迅速传播的冠状病毒SARS-CoV-2正在引发一场毁灭性的大流行。由于我们尚未研发出治愈药物和有效疫苗，这种危及生命的传染病何时结束仍不明朗。重症COVID-19常与高细胞因子血症相关，这在巨噬细胞活化综合征中较为常见。SARS-CoV-2感染在肺部引发这种强烈炎症，并蔓延至呼吸系统，最终导致全身器官功能障碍。尽管我们尚未完全了解COVID-19的生理和病理方面，但目前的研究进展表明抗细胞因子疗法是有效的。在此，我们总结巨噬细胞活化综合征及其对COVID-19的可能影响，以及针对重症COVID-19病例的细胞因子靶向治疗尝试。
